非小细胞肺癌的EGFR表达与EGFR基因突变的比较

目的探讨非小细胞肺癌（NSCLC）表皮生长因子受体（EGFR）免疫组化表达与EGFR基因突变的关系及其临床意义。方法对130例手术切除的非小细胞肺癌组织应用免疫组化方法检测EGFR表达，同时应用基因测序方法检测EGFR基因突变，研究EGFR表达与EGFR基因突变的关系。结果130例NSCLC中有38例EGFR基因突变，突变率为29．2％。EGFR阳性率为67．7％。EGFR表达与基因突变无关（P〉0．05），结论EGFR免疫组化表达与EGFR基因突变无关，不能作为筛选EGFR酪氨酸激酶抑制剂（TKI）治疗NSCLC的指标。

Comparison between EGFR and EGFR mutation in non-small cell lung cancer

Objective To study the relationship between expression of epidermal growth factor receptor （EGFR） and EGFR mutation and its clinical significance in non-small cell lung cancer （NSCLC） .Methods Immunohistochemistry was used to detect the expression of EGFR and gene sequencing was used to determine EGFR mutation in 130 cases of NSCLC, and the relationship between expression of EGFR and EGFR mutation was studied. Results EGFR mutation was found in 38 of 130 cases of NSCLC, the mutation rate was 29.2% .The positive expression rates of EGFR in NSCLC was 66.7% .The expression of EGFR had not correlation with mutation（ P 〉 0.05）. Conclusion The expression of EGFR in NSCLC was not related to EGFR mutation, it was not the predictive marker of tyrosine kinase inhibitors （TKI）response.